|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.040 CNY | -2.27% |
|
-1.31% | -6.93% |
| Market Cap | 4.18B 618M 534M 491M 462M 868M 58.37B 875M 5.81B 2.26B 28.65B 2.32B 2.27B 99.1B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.4B 502M 433M 398M 375M 705M 47.41B 711M 4.72B 1.84B 23.27B 1.89B 1.85B 80.5B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
80.26% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | -2.27% | ||
| 1 week | -1.31% | ||
| Current month | -5.03% | ||
| 1 month | -7.79% | ||
| 3 months | -9.72% | ||
| 6 months | -7.22% | ||
| Current year | -6.93% |
| 1 week | 6.01 |  | 6.31 |
| 1 month | 6 | | 6.62 |
| Current year | 6 | | 7.19 |
| 1 year | 5.86 | | 8.68 |
| 3 years | 4.94 | | 9 |
| 5 years | 4.94 | | 11.9 |
| 10 years | 4.5 | | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 2019-04-22 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 2017-05-16 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 2007-03-10 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 2005-05-25 |
Min Xuan Cui
BRD | Director/Board Member | 66 | 2020-06-15 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 2014-05-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.27% | -1.31% | -2.27% | -12.97% | 633M | |
| +1.09% | +2.33% | +8.02% | +83.51% | 45.7B | |
| +2.03% | +2.87% | +46.54% | +90.11% | 34B | |
| -1.63% | -1.87% | -11.54% | +34.27% | 11.73B | |
| -1.60% | -4.00% | +8.93% | +92.61% | 11.48B | |
| +2.08% | +3.12% | +39.68% | +130.57% | 9.28B | |
| -0.92% | -0.17% | +16.72% | +41.32% | 7.21B | |
| -0.42% | +1.63% | +44.06% | -18.50% | 6.62B | |
| -0.93% | -3.30% | +26.92% | +232.57% | 6.44B | |
| -0.63% | -4.16% | -44.00% | -7.82% | 5.01B | |
| Average | -0.32% | -0.30% | +13.31% | +66.57% | 13.81B | |
| Weighted average by Cap. | +0.58% | +0.49% | +19.17% | +80.98% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 397M 343M 315M 297M 558M 37.51B 562M 3.74B 1.45B 18.41B 1.49B 1.46B 63.69B | 2.24B 331M 286M 263M 247M 465M 31.28B 469M 3.12B 1.21B 15.35B 1.24B 1.22B 53.11B |
| Net income | 243M 35.91M 30.98M 28.48M 26.81M 50.38M 3.39B 50.8M 338M 131M 1.66B 135M 132M 5.75B | 320M 47.35M 40.85M 37.56M 35.35M 66.43M 4.47B 66.99M 445M 173M 2.19B 178M 174M 7.59B |
| Net Debt | -483M -71.46M -61.64M -56.67M -53.34M -100M -6.74B -101M -672M -261M -3.31B -268M -262M -11.45B | -784M -116M -100M -92.06M -86.65M -163M -10.95B -164M -1.09B -425M -5.38B -436M -426M -18.6B |
Employees
3,415
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-16 | 6.040 ¥ | -2.27% | 8,601,871 |
| 26-06-16 | 6.180 ¥ | -0.80% | 7,413,986 |
| 26-06-15 | 6.230 ¥ | -0.95% | 8,668,013 |
| 26-06-12 | 6.290 ¥ | +1.45% | 12,456,630 |
| 26-06-11 | 6.200 ¥ | +0.32% | 8,658,900 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
